Obesity and COVID-19

Abstract

The SARS-CoV-2 respiratory infection pandemic affected more than 317 million people, with approximately 5.5 million deaths worldwide due to the virus. Fifty percent of those who died from COVID-19-related causes had pre-existing cardiovascular or metabolic disease. Multiple publications have described the relationship of the virus with dysmetabolism and obesity, with visceral fat playing a leading role in the complications associated with both diseases. Epicardial and perivascular fat were also related to the severity observed in affected patients. Given the high prevalence of metabolic dysfunction and fatty liver disease (MAFLD), previously called non alcoholic fatty liver disease (NAFLD) in obese individuals, this entity was also associated with greater severity in patients with COVID-19.

Keywords

• obesidad
• covid-19